Impact of hyperthermic intraperitoneal chemotherapy on gastric cancer survival: Peritoneal metastasis and cytology perspectives

Table 1 Comparative demographic characteristics of hyperthermic intraperitoneal chemotherapy, cytology-positive, and cytology-negative patient groups

Feature	Cytology-negative group, n = 41	Cytology-positive group, n = 23	HIPEC group, n = 20	P value
Age	59.87 ± 10.25	63.17 ± 13.57	45.10 ± 11.34	< 0.0001
Sex
Male	23 (56.1)	15 (62.5)	3 (15)	0.002
Female	18 (43.9)	8 (34.8)	17 (85)
Operative time	269.27 ± 98.42	326.43 ± 135.39	534.60 ± 112.76	< 0.0001
Length of stay	14.88 ± 7.76	14.69 ± 6.48	19.05 ± 9.63	0.120
Blood loss	437.56 ± 69.04	616.09 ± 134.64	1056.50 ± 128.03	< 0.0001
Combined resection (other than splenectomy)
No	37 (90)	18 (78.3)	2 (10)	< 0.0001
Yes	4 (9.8)	5 (21.7)	18 (90)
Complication
No	33 (80.5)	17 (73.90)	13 (65.0)	0.419
Yes	8 (19.5)	6 (26.10)	7 (35.0)

Data are n (%). HIPEC: Hyperthermic intraperitoneal chemotherapy.